Table 2.
Meta-analysis: correlation between PD-L1 overexpression and clinicopathologic characteristics
| Outcomes of interest | No of studies | No of patients
|
RR | 95% CI of RR | P-value | Study heterogeneity
|
||||
|---|---|---|---|---|---|---|---|---|---|---|
| PD-L1 high | PD-L1 low | χ2 | df | I2 (%) | P-value | |||||
| Tumor status | 6 | 188 | 410 | 1.04 | 0.85–1.27 | 0.74 | 16.1 | 5 | 69 | 0.007 |
| Pathologic stagea | 3 | 97 | 78 | 1.22 | 0.20–7.64 | 0.83 | 25.3 | 2 | 92 | <0.00001 |
| Metastatic status | 4 | 97 | 152 | 1.40 | 0.88–2.23 | 0.16 | 0.27 | 3 | 0 | 0.97 |
| Differentiation | 6 | 218 | 406 | 1.57 | 1.25–1.98 | 0.0001 | 7.41 | 5 | 33 | 0.19 |
| Lymph node metastasis | 7 | 224 | 414 | 1.09 | 0.97–1.23 | 0.14 | 8.52 | 6 | 30 | 0.20 |
| Vascular invasion | 3 | 105 | 176 | 0.96 | 0.73–1.26 | 0.76 | 1.35 | 2 | 0 | 0.51 |
| Nervous invasion | 4 | 145 | 217 | 1.30 | 1.03–1.64 | 0.03 | 3.79 | 3 | 21 | 0.29 |
Notes:
a
Pathologic stage = TNM stage. RR was calculated for TNM stage III–IV.
Abbreviations: df, degrees of freedom; PD-L1, programmed death-ligand 1; RR, risk ratio.